Achieve Life Sciences (ACHV) Expected to Announce Earnings on Tuesday

Achieve Life Sciences (NASDAQ:ACHV) will likely be posting its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Achieve Life Sciences to post earnings of ($0.27) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 9:30 AM ET.

Achieve Life Sciences Stock Performance

NASDAQ ACHV opened at $4.27 on Friday. Achieve Life Sciences has a twelve month low of $1.84 and a twelve month high of $6.03. The company has a quick ratio of 5.14, a current ratio of 5.14 and a debt-to-equity ratio of 0.26. The stock has a market cap of $227.29 million, a P/E ratio of -3.09 and a beta of 1.81. The company’s 50-day simple moving average is $4.75 and its 200 day simple moving average is $4.21.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ACHV shares. Citigroup assumed coverage on Achieve Life Sciences in a report on Tuesday, November 25th. They set an “outperform” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday, December 29th. Raymond James Financial restated a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Finally, Citizens Jmp assumed coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They issued a “market outperform” rating and a $19.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Institutional Trading of Achieve Life Sciences

Several large investors have recently added to or reduced their stakes in ACHV. KVP Capital Advisors LP acquired a new stake in shares of Achieve Life Sciences during the fourth quarter worth approximately $2,298,000. Millennium Management LLC boosted its holdings in shares of Achieve Life Sciences by 472.3% in the 4th quarter. Millennium Management LLC now owns 1,359,116 shares of the biopharmaceutical company’s stock worth $6,755,000 after acquiring an additional 1,121,614 shares in the last quarter. Jump Financial LLC bought a new stake in Achieve Life Sciences during the 4th quarter worth approximately $104,000. Osaic Holdings Inc. increased its holdings in Achieve Life Sciences by 89.9% during the 4th quarter. Osaic Holdings Inc. now owns 53,983 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 25,550 shares in the last quarter. Finally, Graham Capital Management L.P. acquired a new stake in Achieve Life Sciences during the 4th quarter valued at $212,000. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.